UIH(SH:688271) Xin Lang Cai Jing·2025-10-31 16:12Core Viewpoint - 联影医疗 is a leading player in the domestic medical imaging industry, providing a full range of high-performance medical imaging equipment and solutions, and has successfully broken the foreign monopoly in the high-end medical imaging equipment sector [1] Group 1: Business Performance - In Q3 2025, 联影医疗 reported revenue of 8.859 billion yuan, ranking second among 42 companies in the industry, while the industry leader, 迈瑞医疗, achieved revenue of 25.834 billion yuan [2] - The net profit for 联影医疗 in the same period was 1.102 billion yuan, placing it third in the industry, with 迈瑞医疗 leading at 7.814 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, 联影医疗's asset-liability ratio was 30.08%, higher than the previous year's 26.10% and above the industry average of 27.21% [3] - The gross profit margin for 联影医疗 in Q3 2025 was 47.02%, down from 49.41% year-on-year and below the industry average of 48.67% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders for 联影医疗 increased by 96.28% to 32,400, while the average number of circulating A-shares held per shareholder decreased by 29.23% to 25,400 [5] Group 4: Executive Compensation - The chairman, 张强, received a salary of 2.6521 million yuan in 2024, a decrease of 531,000 yuan from 2023 [4] - The president, JUN BAO, saw a reduction in salary from 2.5667 million yuan in 2023 to 2.2551 million yuan in 2024, a decrease of 311,600 yuan [4] Group 5: Future Outlook - 华泰证券 forecasts that 联影医疗 will achieve a net profit of 2.005 billion yuan in 2025, with projected profits of 2.419 billion yuan and 2.916 billion yuan in 2026 and 2027, respectively [6] - The company is expected to maintain a strong performance in its core equipment business, with significant growth in overseas revenue [6]